Welten M 500mg/20mg Tablet is a fixed-dose combination medication containing Metformin hydrochloride 500mg and Teneligliptin 20mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which enhance glucose-dependent insulin secretion and suppress glucagon release, contributing to improved postprandial and fasting blood glucose levels. This combination is beneficial for patients inadequately controlled on monotherapy or lifestyle interventions alone. Welten M should be used as an adjunct to diet and exercise to optimize glycemic control. The tablet is typically administered orally once or twice daily, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with renal or hepatic impairment, and monitoring of renal function is recommended during therapy. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low but may increase when combined with other antidiabetic agents. Regular monitoring of blood glucose and HbA1c levels is essential to assess therapeutic efficacy and safety.